Bayer rises after Q2 beat, reduced debt outlook

Bayer AG

04/08/2026 07:49

** Shares in Bayer BAYGn.DE rise 3.6% in early Frankfurt trade after the German drugs-to-crop chemicals group posted an unexpected increase in its second quarter adjusted earnings
** Q2 EBITDA, adjusted for one-offs, came in at €2.14 billion ($2.46 billion), above market expectations of €1.94 billion
**Jefferies notes Q2 sales were 2% ahead of consensus, driven mainly by Crop Science and Pharmaceuticals, while core EPS beat expectations by 26%
** The broker adds, however, that the earnings beat was "not sure clean," with Crop Science profit benefiting from insurance proceeds and divestment gains
** Bayer now projects net debt at €29 billion to €30 billion in 2026, down from a range of 32 billion to 33 billion previously forecast
**The stock was up 27.3% YTD as of Monday's close
     
($1 = 0.8690 euros)

(Reporting by Kira Britten)
((Kira.britten@thomsonreuters.com))